196 related articles for article (PubMed ID: 12722735)
1. 5-HT(1)-like receptor agonists and the pathophysiology of migraine.
Saxena PR; Ferrari MD
Trends Pharmacol Sci; 1989 May; 10(5):200-4. PubMed ID: 12722735
[TBL] [Abstract][Full Text] [Related]
2. Clinical and experimental effects of sumatriptan in humans.
Ferrari MD; Saxena PR
Trends Pharmacol Sci; 1993 Apr; 14(4):129-33. PubMed ID: 8390743
[TBL] [Abstract][Full Text] [Related]
3. The biology of serotonin receptors: focus on migraine pathophysiology and treatment.
Hamel E
Can J Neurol Sci; 1999 Nov; 26 Suppl 3():S2-6. PubMed ID: 10563226
[TBL] [Abstract][Full Text] [Related]
4. [The role of serotonin in the pathophysiology of migraine].
Szczudlik A
Neurol Neurochir Pol; 1992; Suppl 2():14-27. PubMed ID: 1337765
[TBL] [Abstract][Full Text] [Related]
5. Sumatriptan: efficacy and contribution to migraine mechanisms.
Pearce JM
J Neurol Neurosurg Psychiatry; 1992 Dec; 55(12):1103-5. PubMed ID: 1336041
[No Abstract] [Full Text] [Related]
6. Migraine: pathophysiology, pharmacology, treatment and future trends.
Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 5HT in migraine.
Buzzi MG
Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654
[No Abstract] [Full Text] [Related]
8. Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential.
Saxena PR; De Vries P; Wang W; Heiligers JP; Maassen vandenBrink A; Bax WA; Yocca FD
Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb; 355(2):295-302. PubMed ID: 9050026
[TBL] [Abstract][Full Text] [Related]
9. Neurogenic inflammation in the context of migraine.
Williamson DJ; Hargreaves RJ
Microsc Res Tech; 2001 May; 53(3):167-78. PubMed ID: 11301492
[TBL] [Abstract][Full Text] [Related]
10. The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine.
Petty MA; Elands J; Johnson MP; Linnik MD; Hamel E; Moskowitz MA; Lee WS; McCarty DR; Hibert M; Baron BM
Eur J Pharmacol; 1997 Oct; 336(2-3):127-36. PubMed ID: 9384224
[TBL] [Abstract][Full Text] [Related]
11. Sumatriptan and cerebral blood flow velocity changes during migraine attacks.
Totaro R; De Matteis G; Marini C; Baldassarre M; Carolei A
Headache; 1997; 37(10):635-9. PubMed ID: 9439084
[TBL] [Abstract][Full Text] [Related]
12. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.
Moskowitz MA
Trends Pharmacol Sci; 1992 Aug; 13(8):307-11. PubMed ID: 1329294
[TBL] [Abstract][Full Text] [Related]
13. [Anti-migraine drug sumatriptan succinate, a 5-HT1B/1D-receptor agonist].
Iwasawa Y; Danjo T
Nihon Yakurigaku Zasshi; 2001 Jun; 117(6):387-93. PubMed ID: 11436516
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of action of the 5-HT1B/1D receptor agonists.
Tepper SJ; Rapoport AM; Sheftell FD
Arch Neurol; 2002 Jul; 59(7):1084-8. PubMed ID: 12117355
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine.
Wang X; Fang Y; Liang J; Yin Z; Miao J; Luo N
Headache; 2010 Apr; 50(4):579-87. PubMed ID: 20236348
[TBL] [Abstract][Full Text] [Related]
16. Serotonin in migraine: theories, animal models and emerging therapies.
Johnson KW; Phebus LA; Cohen ML
Prog Drug Res; 1998; 51():219-44. PubMed ID: 9949863
[TBL] [Abstract][Full Text] [Related]
17. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
Mitsikostas DD; Tfelt-Hansen P
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
[TBL] [Abstract][Full Text] [Related]
18. Triptans. A support to the central link between serotonin and acetylcholine in migraine.
Nicolodi M; Sicuteri F
Adv Exp Med Biol; 1999; 467():183-9. PubMed ID: 10721055
[TBL] [Abstract][Full Text] [Related]
19. Rationale for the use of 5-HT1-like agonists in the treatment of migraine.
Feniuk W; Humphrey PP; Perren MJ; Connor HE; Whalley ET
J Neurol; 1991; 238 Suppl 1():S57-61. PubMed ID: 1646289
[TBL] [Abstract][Full Text] [Related]
20. Eletriptan: pharmacological differences and clinical results.
Giffin N
Curr Med Res Opin; 2001; 17 Suppl 1():s59-62. PubMed ID: 12463280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
